Soligenix, Inc. (SNGX) Dividend History

Company News

• Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

  Soligenix's HyBryte™ treatment showed a 75% positive outcome in early-stage cutaneous T-cell lymphoma (CTCL) patients after 18 weeks, reinforcing its potential as a safe and fast-acting therapy for this rare cancer.

  Benzinga
• TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight

  TALTZ (ixekizumab), an IL-17A inhibitor by Eli Lilly, has shown strong market growth driven by increasing adoption in psoriasis, psoriatic arthritis, and axial spondyloarthritis. With expanding indications and competitive efficacy, it continues to gain market share against rivals.

  GlobeNewswire Inc.

  Featured Companies: AMGN BMY JNJ LLY PFE
• Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

  Soligenix has initiated a confirmatory Phase 3 clinical trial of its drug HyBryte™ for the treatment of cutaneous T-cell lymphoma (CTCL). The trial aims to further demonstrate the efficacy of HyBryte™ in treating CTCL, building on the positive results from the previous Phase 3 study.

  Benzinga
• Soligenix stock rallies 400% on positive HyBryte trial results - Invezz

  Soligenix reported positive interim data from a trial of its HyBryte therapy, with three out of six enrolled patients meeting the success criteria. The company plans to enroll a total of 50 patients and is working towards a confirmatory Phase 3 study.

  Invezz
• Crude Oil Down 1%; Soligenix Shares Surge - Helen Of Troy (NASDAQ:HELE) - Benzinga

  Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.

  Benzinga

  Featured Companies: CLNN HELE QURE